Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Oncogene. 2010 May 13;29(19):2760-71. doi: 10.1038/onc.2010.39. Epub 2010 Mar 15.
Non-small cell lung cancers (NSCLC) that express the cell surface adhesion protein E-cadherin may carry a better prognosis than E-cadherin-negative tumors. Here, we found substantial inhibition of anchorage-independent growth in soft agar and cell migration in each of four NSCLC lines stably transfected with E-cadherin. The inhibitory effects were independent of the EGFR and beta-catenin/Wnt-signaling pathways. However, E-cadherin expression was associated with an adhesion-dependent reduction in the activity of Rho family proteins, RhoA in two lines and Cdc42 in the other two. The reduction of RhoA activity was dependent on DLC-1 Rho-GAP and p190 Rho-GAP and associated with an increase in a membrane-associated p190 Rho-GAP/p120 Ras-GAP complex. In parental cells with high levels of RhoA-GTP, siRNA-mediated knock-down of RhoA reduced cell migration and agar growth in a manner analogous to E-cadherin. In parental cells with high levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migration similarly to cells expressing E-cadherin. Thus, E-cadherin can negatively regulate cell proliferation and migration in NSCLC by reducing the level of the predominant active form of Rho family protein, RhoA or Cdc42. These proteins can be considered downstream effectors of E-cadherin and might represent therapeutic targets in some NSCLC.
表达细胞表面黏附蛋白 E-钙黏蛋白的非小细胞肺癌(NSCLC)可能比 E-钙黏蛋白阴性肿瘤预后更好。在这里,我们发现四个 NSCLC 细胞系中,E-钙黏蛋白稳定转染后,在软琼脂中的锚定非依赖性生长和细胞迁移都受到显著抑制。抑制作用与 EGFR 和β-连环蛋白/Wnt 信号通路无关。然而,E-钙黏蛋白的表达与黏附依赖性 Rho 家族蛋白活性降低有关,两条线中是 RhoA,另外两条线中是 Cdc42。RhoA 活性的降低依赖于 DLC-1 Rho-GAP 和 p190 Rho-GAP,并与膜相关的 p190 Rho-GAP/p120 Ras-GAP 复合物的增加有关。在 RhoA-GTP 水平较高的亲本细胞中,siRNA 介导的 RhoA 敲低以类似于 E-钙黏蛋白的方式降低细胞迁移和琼脂生长。在 Cdc42-GTP 水平较高的亲本细胞中,转染 Cdc42 显性失活突变体同样会降低细胞生长和迁移,类似于表达 E-钙黏蛋白的细胞。因此,E-钙黏蛋白可以通过降低 Rho 家族蛋白主要活性形式 RhoA 或 Cdc42 的水平,负向调节 NSCLC 中的细胞增殖和迁移。这些蛋白可以被视为 E-钙黏蛋白的下游效应物,并且可能成为某些 NSCLC 的治疗靶点。